現在の保管者数(4/15現在)
47,309
これまでの採取実績病院数
1,940施設
Cord Blood with Potential

Cord blood is drawing attention due to its potential in regenerative medicine and cellular therapies, such as diseases that cannot be fully treated at present, like central nervous system disorders (hypoxic-ischemic encephalopathy, cerebral palsy, hearing loss, traumatic encephalopathy and spinal cord injuries, etc.) as well as autoimmune disorders and autistic spectrum disorders and  autism. It is also being used for the treatment of refractory blood diseases, such as leukemia and aplastic anemia.

Foundation research is confirming how cord blood repairs disorders and damage as stem cells in the cord blood migrate (home in on) to the damaged area of the brain, where they relieve inflammation, adjust immunity and activate other cells (cytocrine secretion). Currently, clinical trials on human volunteers are ongoing.

 

Cerebral Palsy
Rate of incidence:2-3 out of 1,000 birth in Japan.
(December 2013 announcement by investigation committee of Japan Obstetric Compensation System)
.
Autism
Rate of incidence:1-2 out of 100 birth in Japan.
(Ministry of Health,Labour and Welfare)
.
Traumatic Brain Injury
This is a brain disorder due to a traffic accident or by falling.
.
Infant Hearing Loss
Rate of incidence:1-2 out of 1,000 birth in Japan.
.
Hypoxic Ischemic Encephalopathy
This is a brain disorder due to disrupted blood flow when there is a prolonged state of apparent death at time of birth.In some cases,this may develop to cerebral palsy.
.

Cord Blood Registry, the leading private bank in the USA, has released a brief review regarding the research and clinical use of the newborn cord blood for various brain disorders including cerebral palsy, traumatic brain injury, stroke, etc. The review says that many scientists believe the cord blood cells have a potential to facilitate repair of the damaged brain tissue. For detail, please read
Newborn Stem Cells from Cord Blood and the Brain.

State of Affairs in Clinical Studies using Autologous Cord Blood

  Domestic:Reports up to November 2018

Condition Phase  Enrollment Institution Primary end date
Hypoxic-ischemic encephalopathy  Ⅰ 6 Osaka City University Hospital Completed (press release published)
Hypoxic-ischemic encephalopathy   Ⅱ  20  Osaka City University Hospital Not Yet Recruiting 
Infantile cerebral palsy  Ⅰ 6 Kochi Medical School Hospital Active, Not Recruiting

  Overseas

Condition  Phase  Enrollment Institution Primary end date
Autism  Ⅱ 29 Sutter Health Completed
(paper published)
Autistic spectrum disorder
  Ⅰ 25 Duke University Completed
(paper published)
Autistic spectrum disorder
  Ⅱ 165 Duke University Active, Not Recruiting
Cerebral palsy   63 Duke University Completed
(paper published) 
Cerebral palsy / Ⅱ 40 Augusta University Recruiting
(Estimated Primary Completion Date; June 2019)
Cerebral palsy Ⅱ  20 Texas University Active, Not Recruiting
Hypoxic ischemic encephalopathy  Ⅰ 52 Duke University Completion
(paper published) 
Hypoxic ischemic encephalopathy  Ⅱ 160 Duke University Recruiting
(Estimated Primary Completion Date; January 2019)
Hypoxic ischemic encephalopathy   Ⅱ 20 New York Medical College Not Yet Recruiting
Hypoplastic left heart syndrome   10 Mayo Clinic Recruiting (case report published)
 Hypoplastic left heart syndrome    12  Melbourne University  Recruiting
(Estimated Primary Completion Date; February 2020)
  Hypoplastic left heart syndrome    60 Sheba Medical Center Not Yet Recruiting
Type I diabetes   Ⅱ 15   Florida University Completed (paper published)
Sensorineural hearing loss   11 Florida Hospital Completed (paper published)

All of the clinical trials listed above are using autologous cord blood. It is considered that the safety and efficiency are lowered when allogeneic cord blood is used.